Pharma News

Methotrexate and the more expensive mycophenolate mofetil performed similarly in a head-to-head clinical trial that compared the two drugs for treating noninfectious uveitis, an eye disease that accounts for up to 15% of blindness in the U. S. In cases of more severe disease, posterior uveitis and panuveitis, the international trial showed that methotrexate was more effective in controlling inflammation.

Methotrexate and the more expensive mycophenolate mofetil performed similarly in a head-to-head clinical trial that compared the two drugs for treating noninfectious uveitis, an eye disease that accounts for up to 15% of blindness in the U. S. In cases of more severe disease, posterior uveitis and panuveitis, the international trial showed that methotrexate was more effective in controlling inflammation. Investigators published results from the trial today in the Journal of the American Medical Association. The National Eye Institute, part of the National Institutes of Health, funded the trial.

Eminence Business Media’s “Pharma Brand Protection & Packaging 2019” concluded on August 29 th  & 30 th , 2019 at Hotel Novotel, Mumbai.The theme of the summit was “Trends that have revolutionized the Pharma Packaging World”.The event was an outstanding success with 150+ delegates attending the conference with Karomi Technologies, Autoprint Machinery Manufacturers Pvt. Ltd, Condot Systems, Original 4 Sure, Great Four Systems Pvt. Ltd., Bobst India, Novel Automation Ltd., Bullion Flexipack Pvt. Ltd, Pharma Secure, Aptar Pharma, Nipro Pharma Packaging, Systech International, Immer Group, Sun Packaging, Nuplas Industries, Pharma Mantra, GS1 India, PCRI & ASPA partnering the event.

Pharma major Lupin Limited (Lupin) announced that it has received approval for its Ethacrynic Acid Tablets USP, 25 mg, from the United States Food and Drug Administration (U.S. FDA).

Boehringer Ingelheim and Lupin Limited (Lupin) joined in for a licensing, development and commercialization agreement for Lupin's MEK inhibitor compound (LNP3794) as a potential targeted therapy for patients with difficult-to-treat cancers.

The past 10 years have been very crucial for the Indian Pharma Landscape.  From 2005-2015; the revenue of the top 10 companies grew at 19% which is almost at par with the industry growth of 18%. Things have significantly changed now with US markets capping prices of crucial drugs that have impacted the overall profit margins.
Indian pharma companies have to nimbly navigate contingencies by expanding the number of FDA approved sites to secure a dominant position in the US market. The US contributes about one third of the total Indian pharma exports. Furthermore, Indian pharma manufacturing companies accounted for 34 per cent of the total ANDA approvals by the US in 2016.

Combining the PD-1 immune check point inhibitor nivolumab with the monoclonal antibody ipilimumab showed a consistent safety profile in special populations with advanced non-small cell lung cancer (NSCLC), according to research presented today by at the IASLC 2019 World Conference on Lung Cancer hosted by the International Association for the Study of Lung Cancer.

The rate of chronic hypertension among pregnant women age 35 and over in the United States has increased by more than 75% since 1970, with black women suffering from persistent high blood pressure at more than twice the rate of white women, according to a Rutgers study.

Scientists from the National Institutes of Health and Cincinnati Children’s Hospital Medical Center have devised a potential treatment against a common type of leukemia that could have implications for many other types of cancer. The new approach takes aim at a way that cancer cells evade the effects of drugs, a process called adaptive resistance.